Executive Brief on Nasal Decolonization: The importance of advances in nasal decolonization for current and future infection prevention

Free Download Below.

Executive Brief on Nasal Decolonization

Nasal carriage of Staphylococcus aureus is reported in 30% of the population, and methicillin-resistant Staphylococcus aureus (MRSA) in 3% to 5% percent of the population. These are major risk factors for infection in healthcare environments. Clinical evidence reveals that nasal decolonization can significantly reduce the risk of transmission. This can help address the dilemma of contact precautions (CP) where patients remain colonized. New infection prevention programs using alcohol-based Nozin® Nasal Sanitizer® antiseptic allow for wider application of nasal decolonization than previously available with significant reduction of infection risks, improvements in patient care as well as potential for substantial CP cost savings in the ICU, OR and other high-risk areas.

Download PDF to read more.


Health Professionals:
Request a comprehensive analysis of your colonization risk mitigation protocols today.

© 2004-2023 Global Life Technologies Corp. All rights reserved. All trademarks are property of their respective owners. Nozin® Nasal Sanitizer® antiseptic is an OTC topical antiseptic drug and no claim is made that it has an effect on any specific disease. | Patent Nos.